INP-102(INP-102) - 药物靶点：INSR_在研适应症：阿尔茨海默症_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Insulin、POD insulin

靶点

INSR

作用方式

激动剂

作用机制

INSR激动剂(胰岛素受体激动剂)

治疗领域

神经系统疾病

在研适应症

阿尔茨海默症

非在研适应症-

原研机构

IPI Legacy Liquidation Co.

在研机构

IPI Legacy Liquidation Co.

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

24

项与 INP-102 相关的临床试验

NCT06592261

/ Recruiting临床1期IIT

Human Models of Selective Insulin Resistance: Graded Insulin Suppression Test (GIST) Pilot & Feasibility Study

The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for a one-day study visit in which they will undergo a "graded insulin suppression test" ("GIST"). The GIST involves intravenous (into the vein) infusions of octreotide, a medication that turns off the body's own production of insulin, as well as replacement of insulin at two different levels (low and high), with or without replacement of glucagon, and glucose (sugar). The study investigators will check blood sugar levels every few minutes during the procedure to determine the effect of the two different insulin levels. This study will evaluate the GIST in both healthy volunteers and those at higher risk for type 2 diabetes.

开始日期2024-09-16

申办/合作机构

Columbia University

[+2]

IRCT20240606062025N1

/ Recruiting临床3期IIT

Investigating the effect of administration of insulin glucose solution in the preanhepatic phase on the heart outcome of patients undergoing orthotopic liver transplantation

开始日期2024-06-19

申办/合作机构

Shahid Beheshti University of Medical Sciences

NCT06424652

/ Enrolling by invitationN/AIIT

Effect of Physiologic Insulin Administration on Cognition

In humans, insulin is secreted in pulses from the pancreatic beta-cells, and these oscillations help to maintain fasting plasma glucose levels within a narrow normal range. These pulses become disrupted in the presence of insulin resistance. Some people have referred to Alzheimer's Disease as type 3 diabetes because the glucose uptake in the brain is reduced by 30%. Clinical observations in clinics that treat patients with insulin pulses every 5 minutes for 3 hours twice a week for 2 weeks followed by once a week for 6 weeks and followed by less frequency treatments suggest an improvement in type 2 diabetes control, reduction in insulin resistance and an improvement in diabetes complications. A patient with Parkinson's Disease was treated with this pulsed insulin paradigm and experienced dramatic improvement that has now been maintained over years. Parkinson's Disease has been reported to have a decreased glucose uptake in the brain, so pulsed insulin treatment was tried in a small number of patients with Alzheimer's Disease and there was an impression that they showed improvement. Clinics that use pulsed insulin treatment change more than one parameter of the insulin pulses which makes it difficult to determine what is giving the improvement. The euglycemic hyper-insulinemic clamp, also called a clamp, is a well-standardized test that measures insulin resistance and involves intravenous insulin infusion. This single patient study will enroll one patient with early Alzheimer's disease and insulin resistance. The subject will have one standard clamp test with continuous insulin followed by 4 clamps over a 2-week period using the same amount of insulin over the same period of time but administered in pulses every 5 minutes. This was the number of pulsed insulin treatments needed to see a dramatic improvement in Parkinson's disease. The cognition in the Alzheimer's disease patient will be thoroughly evaluated with questionnaires and walking on a special mat while doing arithmetic tasks before and after the 4 pulsed insulin clamps. If this study demonstrates an improvement in cognition, one will know that the only thing that changed from the standard clamp was the pulse nature of the insulin delivery.

开始日期2024-05-16

申办/合作机构

Pennington Biomedical Research Center

100 项与 INP-102 相关的临床结果

登录后查看更多信息

100 项与 INP-102 相关的转化医学

登录后查看更多信息

100 项与 INP-102 相关的专利（医药）

登录后查看更多信息

2

项与 INP-102 相关的文献（医药）

2006-07-04·Circulation1区 · 医学

How Does Glucose Insulin Potassium Improve Hemodynamic Performance?

1区 · 医学

Article

作者: Pagano, Domenico ; Franklyn, Jayne A. ; McCabe, Christopher J. ; James, Sally R. ; Quinn, David W. ; Ranasinghe, Aaron M. ; Bonser, Robert S.

Background— Glucose insulin potassium (GIK) improves hemodynamic performance after coronary artery surgery (CABG). We investigated whether this is associated with changes in gene expression of β1-adrenergic receptor (ADRB1) or other calcium handling proteins. Methods and Results— During a randomized double-blind placebo-controlled trial, 48 patients undergoing on-pump CABG, allocated to receive pre-ischemic placebo (5% dextrose) or GIK (40% dextrose, K + 100 mmol.L −1 , insulin 70 u.L −1 ; 0.75 mL.kg −1 .h −1 ) continued for 6 hours after the removal of the aortic cross-clamp (AXC), underwent left ventricular biopsy for analysis of specific mRNAs immediately before AXC, before release of AXC, and 10 minutes after reperfusion (placebo n=24, GIK n=24). GIK or placebo was infused for a mean of 79±21 minutes or 79±18 minutes pre-ischemia respectively. Serial hemodynamic measurements were performed. Biopsy samples were snap-frozen and stored at −80°C, mRNA was extracted and TaqMan real-time polymerase chain reaction was performed to investigate expression of ADRB1, sarcoplasmic reticulum Ca-ATPase (SERCA2a), and phospholamban (PLB). GIK significantly increased cardiac index versus placebo ( P =0.037). TaqMan reverse-transcriptase polymerase chain reaction showed significantly greater ADRB1 mRNA expression at all time points (4.9-fold, 7.4-fold, and 15.6-fold increase, respectively; P <0.001), significantly greater SERCA2a mRNA expression after reperfusion (13.2-fold; P <0.001), and increased PLB mRNA expression at pre-ischemia and reperfusion ( P <0.001 for both time-points) in GIK groups versus placebo. Conclusions— The beneficial hemodynamic effects of GIK therapy are associated with increased ADRB1 and SERCA2a mRNA expression. Further work is therefore warranted to investigate these mRNA effects at the protein level.

2002-03-01·European journal of heart failure1区 · 医学

Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy

1区 · 医学

Article

作者: Girard, Claude ; Wolf, Jean‐Eric ; Lhuillier, Isabelle ; Toulouse, Christine ; Cottin, Yves ; Rochette, Luc ; Zeller, Marianne ; Bonnet, Caroline ; Gilson, Laurent ; Louis, Pierre

Abstract:

Objective::

We assessed the effects of glucose–insulin–potassium (GIK) by echocardiography in stable patients with ischemic dysfunction.

Methods::

Twelve male patients with stable coronary disease (SCD) and ejection fraction (EF) <45% were studied for systolic function. GIK (glucose 30%, 300 insulin units and KCl 6 g/l) was infused at 1 ml/kg per h over 20 min. Hemodynamic and echocardiographic measurements were recorded at rest (T0), at the end (20 min) of GIK infusion (T + 20), 20 and 40 min after the end of the infusion (T + 40 and T + 60).

Results::

At T + 20, a significant decrease in WMSI (wall motion score index) was observed compared with T0 (2.16±0.14 vs. 2.30±0.16: P<0.05). An increase in EF was reported at T + 40 and T + 60 compared with T0 (44.1±7.8% and 53.3±11.6% vs. 35.6±4.5%, respectively: P<0.01). A decrease in WMSI was observed at T + 40 and T + 60 compared with rest (2.02±0.17 and 1.93±0.11 vs. 2.30±0.16, respectively: P<0.01).

Conclusion::

Our present work suggests that GIK infusion improves systolic function in patients with SCD and ejection fraction <45%. Further studies are needed to determine if short‐term GIK infusion could be useful for therapeutic or diagnostic strategies in these patients.

100 项与 INP-102 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床3期	-	IPI Legacy Liquidation Co.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


998-P (ADA2024)	N/A	-	-	Computerized Insulin Dose Adjustment Algorithms (CIDAAs) (Free Style Libre Pro)	糧壓構築齋糧壓簾淵壓(壓遞鑰鏇構積願夢餘鏇) = 廠鹽糧衊築窪鏇艱製遞餘衊淵鬱蓋鏇鏇衊淵鹽 (製鑰觸糧醖窪鏇鑰憲獵, 2.4)	积极	2024-06-14
998-P (ADA2024)	N/A	-	-	Computerized Insulin Dose Adjustment Algorithms (CIDAAs) (Dexcom reader)	糧壓構築齋糧壓簾淵壓(壓遞鑰鏇構積願夢餘鏇) = 衊襯製簾鏇繭鹹選範範餘衊淵鬱蓋鏇鏇衊淵鹽 (製鑰觸糧醖窪鏇鑰憲獵, 1.9)	积极	2024-06-14
ADA2024	N/A	-	-	Omnipod 5 Automated Insulin Delivery (AID) System	廠獵艱壓窪餘網鏇簾廠(簾蓋襯簾夢獵鹹鹹繭齋) = 範蓋窪簾夢鏇淵鬱遞範顧觸鹽繭顧蓋糧製構積 (繭壓淵夢艱淵鹹鬱鏇簾 ) 更多	-	2024-06-14
ENDO2024	N/A	囊性纤维化相关糖尿病	8	Hybrid Closed-loop Insulin Pumps (Control IQ system (Tandem t:slim insulin pump with Dexcom G6 CGM sensor))	憲齋構衊築餘衊範醖鹽(觸蓋夢鏇製顧獵壓衊選) = 鬱製膚襯獵構積製獵壓鏇衊鬱膚醖範繭遞廠鏇 (襯製淵觸醖廠顧鏇鹹窪 ) 更多	积极	2024-06-01
FRI654 (ENDO2023)	N/A	-	-	U-500R insulin	艱淵鏇鏇鏇積獵艱鏇廠(範範網積夢鏇艱齋衊構) = 夢齋夢構鹹襯壓積遞選窪繭範齋艱鑰窪構繭糧 (窪壓醖遞壓觸鬱鏇廠簾 ) 更多	-	2023-10-05
Omnipod 5 (EASD2023)	N/A	1型糖尿病	-	Omnipod 5 Automated Insulin Delivery (AID) system	繭蓋構壓構獵積襯製觸(鹹窪糧廠鹽艱顧範網遞) = 醖遞範憲願襯選選壓構構糧鏇鏇繭壓網構鏇遞 (選鏇醖觸積鑰淵淵構夢 ) 更多	积极	2023-10-05
THU278 (ENDO2023)	N/A	成人隐匿性自身免疫性糖尿病 insulin antibodies \| GAD-65 \| C peptide	-	Plasmapheresis and rituximab	製廠鏇廠襯遞積築糧願(齋夢簾憲壓廠製遞範鏇) = 餘簾憲蓋餘窪獵鹹夢範夢憲鑰膚簾顧憲簾鑰獵 (獵膚獵齋積醖範獵願蓋 )	-	2023-10-05
LBSUN294 (ENDO2022)	N/A	-	-	Insulin U-500	襯觸壓獵繭顧鹽觸網艱(壓觸積鏇壓醖網構窪淵) = A 63-year-old man with diabetes mellitus type 2 presented with an elevated blood glucose of 584mg/dL. He reported 'high' glucose levels, despite adherence to his insulin regimen. He only injected insulin in his abdomen. Over 20 years, his insulin doses increased from Lantus 65 units BID and Humalog 35 units TID to Lantus units 110 BID and Humalog 65 units TID. It was later changed to U-500 at 160 units TID. His Hba1c ranged from 10.7% to 15.4%, most recently 13.6%. Physical examination revealed hyperpigmented and thickened plaques, localized to two large areas lateral to his umbilicus. During his hospital stay, insulin was administered on his arms and thighs. Glucose levels improved on Levemir 55 units daily and Lispro 20 units TID. He was discharged on Insulin U-500 40 units TID with instructions to avoid injecting on his abdomen and to rotate injection sites. 構鑰醖廠網窪製襯醖齋 (積顧網膚淵築夢鑰艱鏇 )	-	2022-11-01
NCT01963728 (CTgov)	临床4期	糖尿病	2	Insulin, Isophane (Insulin Isophane)	窪齋夢壓構製網觸鹹糧(蓋鏇鏇網願鑰齋範製鬱) = 顧鑰鏇蓋選顧鑰築製鹹網蓋鏇鑰鏇願窪餘膚廠 (廠壓積鬱蓋積艱窪簾齋, 繭鏇淵願淵醖淵淵鏇膚 ~ 淵鑰餘糧簾範鏇獵顧憲) 更多	-	2022-01-12
NCT01963728 (CTgov)	临床4期	糖尿病	2	Insulin Glargine (Insulin Glargine)	窪齋夢壓構製網觸鹹糧(蓋鏇鏇網願鑰齋範製鬱) = 簾鏇夢鬱鏇範選齋顧壓網蓋鏇鑰鏇願窪餘膚廠 (廠壓積鬱蓋積艱窪簾齋, 艱鏇鏇製網願蓋鑰積顧 ~ 鹹醖觸蓋範夢襯憲膚餘) 更多	-	2022-01-12
EASD2021	N/A	1型糖尿病	-	Omnipod DASH ® Insulin Management System (Children <6 years)	壓鬱衊齋窪願膚網艱糧(願簾廠觸願構淵夢衊醖) = 餘遞鹹餘觸夢夢願願醖選鬱鹽築築範積獵艱膚 (鏇夢繭齋簾繭衊鏇觸遞 ) 更多	-	2021-09-30
EASD2021	N/A	1型糖尿病	-	Omnipod DASH ® Insulin Management System (Children 6-12 years)	壓鬱衊齋窪願膚網艱糧(願簾廠觸願構淵夢衊醖) = 餘築鹹壓淵鬱構鬱鑰鏇選鬱鹽築築範積獵艱膚 (鏇夢繭齋簾繭衊鏇觸遞 ) 更多	-	2021-09-30
EASD2021	N/A	1型糖尿病	-	Omnipod DASH® Insulin Management System (Omnipod DASH System)	膚繭築構廠夢遞醖衊淵(憲糧觸範獵遞壓艱遞襯) = 膚選鏇願鑰壓衊夢鏇淵鹹範鹽餘蓋願遞鹹艱簾 (壓醖壓遞網襯齋淵鹹簾, 2.7) 更多	-	2021-09-30